Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2000

01-12-2000 | Paper Report

Deficiency of Il-1ra may predispose to development of arthritis

Author: Oliver Fitzgerald

Published in: Arthritis Research & Therapy | Issue 1/2000

Login to get access

Excerpt

Rheumatoid arthritis (RA) is a chronic systemic disease which commonly results in joint damage and consequent disability. Various pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF)-a are overexpressed in the joints of RA patients. IL-1 is thought to be a major mediator of inflammation as it exerts a number of biological activities by binding the IL-1 type I receptor. IL-1ra is a naturally occurring inhibitor of IL-1 which competes for the receptor. Previous studies have suggested that IL-1ra production may be relatively deficient or inadequate in RA patients. IL-1ra gene polymorphism has not, as yet, been reported in RA in humans. To study the pathophysiological roles of IL-1ra in regulating the inflammatory response. …
Literature
1.
go back to reference Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000, 191: 313-320.PubMedPubMedCentralCrossRef Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000, 191: 313-320.PubMedPubMedCentralCrossRef
Metadata
Title
Deficiency of Il-1ra may predispose to development of arthritis
Author
Oliver Fitzgerald
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar-2000-66798

Other articles of this Issue 1/2000

Arthritis Research & Therapy 1/2000 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine